Khianne Ed Miguel P. Orteza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Khianne Ed Miguel P. Orteza has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Carol Stephanie Chua Tan-Lim
Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines
2 shared publications - Ma. Easter Joy V. Sajo
Department of Biology, University of the Philippines Baguio
2 shared publications Ma. Junella C. Vila
Department of Biology, College of Science University of the Philippines Baguio Baguio City Philippines
2 shared publicationsPatricia Barbara A. Fernandez
Department of Biology, College of Science University of the Philippines Baguio Baguio City Philippines
2 shared publications
Latest Publications
- 21 September 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (9) , e14022
Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis
Background: Due to the recency of the postbiotic field, no head‐to‐head postbiotic studies have investigated its biotherapeutic potential for atopic dermatitis (AD). No network meta‐analysis (NMA) has been conducted to synthesize relevant studies comparing postbiotic interventions for AD.Objective: To assess the comparative efficacy and safety of postbiotic strains in the treatment of pediatric AD.Methodology: This was an NMA of randomized controlled studies that evaluated postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, and appraisal using the Cochrane risk‐of‐bias tool version 2 and data extraction. Data analysis was performed using STATA14 software.Results: Nine studies evaluated eight postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis in the main analysis (SMD −0.53, 95%CI −1.02 to −0.04) and sensitivity analysis involving studies that used SCORAD (MD −5.52, 95% CI −10.46 to −0.58), based on low‐certainty evidence. Based on moderate‐certainty evidence, LR probably did not increase the risk of adverse events (RR 0.97, 95% CI 0.79, 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD −0.03, 95% CI −0.37, 0.32) based on low‐certainty evidence.Conclusion: LR showed significant benefits in children with AD based on low‐certainty evidence. Further investigation of LR is recommended.
- 21 September 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (9) , e14022
Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis
Background: Due to the recency of the postbiotic field, no head‐to‐head postbiotic studies have investigated its biotherapeutic potential for atopic dermatitis (AD). No network meta‐analysis (NMA) has been conducted to synthesize relevant studies comparing postbiotic interventions for AD.Objective: To assess the comparative efficacy and safety of postbiotic strains in the treatment of pediatric AD.Methodology: This was an NMA of randomized controlled studies that evaluated postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, and appraisal using the Cochrane risk‐of‐bias tool version 2 and data extraction. Data analysis was performed using STATA14 software.Results: Nine studies evaluated eight postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis in the main analysis (SMD −0.53, 95%CI −1.02 to −0.04) and sensitivity analysis involving studies that used SCORAD (MD −5.52, 95% CI −10.46 to −0.58), based on low‐certainty evidence. Based on moderate‐certainty evidence, LR probably did not increase the risk of adverse events (RR 0.97, 95% CI 0.79, 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD −0.03, 95% CI −0.37, 0.32) based on low‐certainty evidence.Conclusion: LR showed significant benefits in children with AD based on low‐certainty evidence. Further investigation of LR is recommended.
- Open Access
- 17 April 2023
- Published by Wiley
Next-Gen Biotherapeutics: A Systematic Review and Network Meta-Analysis on Postbiotics as Treatment For Pediatric Atopic Dermatitis
Background: Due to the recency of the postbiotic field, there are no head-to-head postbiotic studies investigating its biotherapeutic potential for atopic dermatitis (AD). No network meta-analysis (NMA) has yet been conducted to synthesize relevant studies to compare postbiotic interventions for AD. Objective: To assess the comparative efficacy and safety of postbiotic strains for treating pediatric AD. Methodology: This is an NMA of randomized controlled studies that evaluate postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, appraisal using the Cochrane risk of bias tool version 2 and data extraction. Data analysis was done using STATA14 software. Results: There were 9 studies that evaluated 8 postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis both in the main analysis (SMD -0.53, 95%CI -1.02 to -0.04) and sensitivity analysis involving studies that used SCORAD (MD -5.52, 95% CI -10.46 to -0.58), based on low-certainty evidence. Based on moderate-certainty evidence, LR probably does not increase the risk of adverse events (RR 0.97, 95% CI 0.79 to 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD -0.03, 95% CI -0.37 to 0.32) based on low-certainty evidence. Conclusion: LR showed significant benefits for children with AD, based on low-certainty evidence. Further investigation on LR is recommended.
- 17 April 2023
- Published by Wiley
Open AccessNext-Gen Biotherapeutics: A Systematic Review and Network Meta-Analysis on Postbiotics as Treatment For Pediatric Atopic Dermatitis
Background: Due to the recency of the postbiotic field, there are no head-to-head postbiotic studies investigating its biotherapeutic potential for atopic dermatitis (AD). No network meta-analysis (NMA) has yet been conducted to synthesize relevant studies to compare postbiotic interventions for AD. Objective: To assess the comparative efficacy and safety of postbiotic strains for treating pediatric AD. Methodology: This is an NMA of randomized controlled studies that evaluate postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, appraisal using the Cochrane risk of bias tool version 2 and data extraction. Data analysis was done using STATA14 software. Results: There were 9 studies that evaluated 8 postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis both in the main analysis (SMD -0.53, 95%CI -1.02 to -0.04) and sensitivity analysis involving studies that used SCORAD (MD -5.52, 95% CI -10.46 to -0.58), based on low-certainty evidence. Based on moderate-certainty evidence, LR probably does not increase the risk of adverse events (RR 0.97, 95% CI 0.79 to 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD -0.03, 95% CI -0.37 to 0.32) based on low-certainty evidence. Conclusion: LR showed significant benefits for children with AD, based on low-certainty evidence. Further investigation on LR is recommended.